Analysts Issue Forecasts for FULC FY2030 Earnings

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) – Equities research analysts at HC Wainwright issued their FY2030 earnings estimates for Fulcrum Therapeutics in a research note issued to investors on Tuesday, February 24th. HC Wainwright analyst A. Maldonado expects that the company will post earnings of $2.71 per share for the year. HC Wainwright currently has a “Buy” rating and a $25.00 target price on the stock. The consensus estimate for Fulcrum Therapeutics’ current full-year earnings is ($0.16) per share.

Several other research firms have also recently issued reports on FULC. JPMorgan Chase & Co. started coverage on Fulcrum Therapeutics in a research report on Monday, January 12th. They issued an “overweight” rating and a $20.00 price objective for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Fulcrum Therapeutics in a research note on Thursday, January 22nd. Royal Bank Of Canada raised their price objective on shares of Fulcrum Therapeutics from $7.00 to $10.00 and gave the company a “sector perform” rating in a research note on Monday, December 8th. Truist Financial set a $17.00 price objective on shares of Fulcrum Therapeutics in a report on Tuesday. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $23.00 target price (up from $16.00) on shares of Fulcrum Therapeutics in a report on Monday, December 8th. Seven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, Fulcrum Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $19.00.

Fulcrum Therapeutics Price Performance

FULC opened at $8.58 on Wednesday. Fulcrum Therapeutics has a 12 month low of $2.32 and a 12 month high of $15.74. The stock has a market capitalization of $464.35 million, a P/E ratio of -7.27 and a beta of 3.19. The business has a 50 day simple moving average of $10.79 and a 200-day simple moving average of $9.48.

Fulcrum Therapeutics (NASDAQ:FULC) last announced its quarterly earnings data on Tuesday, February 24th. The company reported ($0.31) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.31).

Insider Activity

In other Fulcrum Therapeutics news, Director Robert J. Gould sold 15,000 shares of the firm’s stock in a transaction dated Friday, January 2nd. The shares were sold at an average price of $11.87, for a total transaction of $178,050.00. Following the completion of the transaction, the director directly owned 469,864 shares in the company, valued at approximately $5,577,285.68. This trade represents a 3.09% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, major shareholder Ra Capital Management, L.P. sold 4,175,139 shares of Fulcrum Therapeutics stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $13.98, for a total transaction of $58,368,443.22. Following the transaction, the insider owned 6,053,960 shares of the company’s stock, valued at approximately $84,634,360.80. The trade was a 40.82% decrease in their position. The disclosure for this sale is available in the SEC filing. 7.00% of the stock is owned by insiders.

Institutional Investors Weigh In On Fulcrum Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Aberdeen Group plc raised its holdings in shares of Fulcrum Therapeutics by 135.0% in the third quarter. Aberdeen Group plc now owns 137,961 shares of the company’s stock worth $1,269,000 after acquiring an additional 79,265 shares during the last quarter. Acadian Asset Management LLC raised its stake in Fulcrum Therapeutics by 63.5% in the 2nd quarter. Acadian Asset Management LLC now owns 563,380 shares of the company’s stock valued at $3,871,000 after purchasing an additional 218,819 shares during the last quarter. Bailard Inc. acquired a new position in Fulcrum Therapeutics in the 2nd quarter valued at about $185,000. Campbell & CO Investment Adviser LLC purchased a new position in Fulcrum Therapeutics in the 3rd quarter valued at about $943,000. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its stake in shares of Fulcrum Therapeutics by 57.3% during the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 342,547 shares of the company’s stock worth $2,357,000 after purchasing an additional 124,798 shares during the last quarter. Hedge funds and other institutional investors own 89.83% of the company’s stock.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.